AI assistant
CAMBIUM BIO LIMITED — Director's Dealing 2020
Nov 18, 2020
64666_rns_2020-11-18_6fdbbef1-df70-41b8-9202-d0d90bb606a7.pdf
Director's Dealing
Open in viewerOpens in your device viewer
19 November 2020
==> picture [160 x 33] intentionally omitted <==
ASX Announcement
Lapse of Unlisted Share Options
Regeneus Ltd (ASX: RGS) ( Regeneus or the Company ), a clinical-stage regenerative medicine company, advises that the following unlisted share options granted pursuant to Regeneus’ option share trust plan have lapsed with the resignation of Leo Lee as CEO.
| cne company, avsesRegeneus’ option share tr | a e oowng unse sare opons grane purust plan have lapsed with the resignation of Leo Lee as | a e oowng unse sare opons grane purust plan have lapsed with the resignation of Leo Lee as | a e oowng unse sare opons grane purust plan have lapsed with the resignation of Leo Lee as | |
|---|---|---|---|---|
| L | apsed Options | Exercise Price | Expiry Date | |
| 2 | ,500,000 | $0.25 | 31/1/2024 | |
| 3 | 500000 | $015 | 1/10/2024 | |
| ,, | . | |||
| 7 | 50,000 | $0.20 | 1/10/2024 | |
| 7 | ||||
| 50,000 | $0.25 | 1/10/2024 | ||
| 7 | 50,000 | $0.30 | 1/10/2024 | |
| 7 | 50,000 | $0.35 | 1/10/2024 | |
In addition to the share options that have lapsed as detailed above, as a result of his resignation as CEO and change from an executive to a non-executive director, Leo Lee has not, and will not be issued any of the 12,250,000 options approved by shareholders for issue to him at the 2020 AGM held on 14 October 2020.
The total number of options remaining on issue following the lapse of the above options are as follows:
| are asfollows: | ||
|---|---|---|
| Number of Options | Exercise Price | Expiry Date |
| 1,250,000 | $0.20 | 31/1/2024 |
| 1,000,000 | $0.10 | 30/09/2024 |
| 2,980,770 | $0.10 | 30/06/2025 |
| 1,029,500 | $0.14 | 31/08/2025 |
| 2,000,000 | $0.1075 | 31/08/2025 |
-ENDS-
About Regeneus
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.
2 Paddington Street, Paddington, NSW 2021 Ph: +61 2 9499 8010 • www.regeneus.com.au • ABN 13 127 035 358
==> picture [160 x 33] intentionally omitted <==
Authorisation & Additional information
This announcement was authorised by the Board of Directors of Regeneus Ltd
Investor and Media Contact
WE Communications T: 02 9237 2805
2 Paddington Street, Paddington, NSW 2021 Ph: +61 2 9499 8010 • www.regeneus.com.au • ABN 13 127 035 358